Meta-analysis confirms raised risk of bladder cancer from pioglitazoneBMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e4541 (Published 04 July 2012) Cite this as: BMJ 2012;345:e4541
- Barbara Kermode-Scott
- 1 Edmonton
A new meta-analysis1 seems to confirm findings from a nested, case-control study published in the BMJ in May2 that thiazolidinediones are associated with an increased risk of bladder cancer in people with type 2 diabetes.
Both analyses also found that in the studies that looked at individual drugs in this class pioglitazone, but not rosiglitazone, was associated with an increased risk of bladder cancer.
In the BMJ study, Azoulay and colleagues from McGill University in Montreal looked at a cohort that included 115 727 new users of oral hypoglycaemic agents, of whom 470 were given a diagnosis of bladder cancer during follow-up …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial